Clinical Trial: The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07198516) titled 'The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:' on Aug. 17.

Brief Summary: To evaluate the effect and safety of Henggliejin on fatty liver in type 2 diabetes patients with nonalcoholic fatty liver disease

Study Start Date: Nov. 01

Study Type: INTERVENTIONAL

Condition: NAFLD Diabete Type 2

Intervention: DRUG: Addition of Hengge Liejing treatment for 48 weeks

Treatment with Hengge Liejing for 48 weeks, drug formulation: tablets. Dosage: 10mg qd, taken orally in the morning, before or after breakfast, for 48 consecutive weeks

Recruitment Status: NOT_YET_RECRUITING...